PremiumThe FlyAkero Therapeutics price target raised to $75 from $72 at H.C. Wainwright Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position PremiumThe Fly89bio initiated with an Outperform at Wolfe Research 89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’ Akero Therapeutics price target raised to $109 from $42 at UBS PremiumThe FlyAkero Therapeutics 5.333M share Secondary priced at $48.00 Akero Therapeutics price target raised to $96 from $46 at Morgan Stanley Akero Therapeutics price target raised to $73 from $56 at Canaccord 
